SCHEMBL6356880

SCHEMBL6356880

O=C(NCc1ccc(F)cc1C(F)(F)F)c1cc(Cl)ccc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.56
LMNA P02545 1/20 0.56
EPHX2 P34913 3/20 0.49
P2RX7 Q99572 5/20 0.48
PPARG P37231 2/20 0.48
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C19 P33261 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
P2RX1 P51575 1/20 0.46
TMPRSS4 Q9NRS4 1/20 0.46
KDM4E B2RXH2 1/20 0.45
DDR1 Q08345 2/20 0.45
GCGR P47871 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6356836 0.86 KDM4E (0.52) HPGDLMNAEPHX2P2RX7PPARG
SCHEMBL6357645 0.86 ALDH1A1 (0.53) HPGDLMNAEPHX2P2RX7CYP1A2
SCHEMBL6357851 0.83 CNR1 (0.55) HPGDLMNAP2RX7PPARGCYP1A2
SCHEMBL6362493 0.82 P2RX7 (0.49) HPGDLMNAEPHX2P2RX7PPARG
SCHEMBL6355300 0.82 EPHX2 (0.55) EPHX2P2RX7PPARGHDAC3HDAC1
SCHEMBL6355022 0.80 EPHX2 (0.53) LMNAEPHX2P2RX7PPARGHDAC3
SCHEMBL6361826 0.79 P2RX7 (0.51) LMNAEPHX2P2RX7HDAC1HDAC6
SCHEMBL6361087 0.78 CA1 (0.67) HPGDLMNAPPARGCYP1A2CYP3A4
SCHEMBL6357804 0.77 ALDH1A1 (0.62) HPGDLMNAP2RX7CYP1A2CYP3A4
SCHEMBL6357056 0.77 EPHX2 (0.49) LMNAEPHX2P2RX7HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US claimed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP claimed
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists ONO PHARMACEUTICAL CO., LTD. (JP) 2005-01-13 US disclosed
EP-1438973-A1 REMEDIES FOR STRESS DISEASES COMPRISING MITOCHONDRIAL BENZODIAZEPINE RECEPTOR ANTAGONISTS ONO PHARMACEUTICAL CO., LTD. (JP) 2004-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009812-A1 Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists TFAM, CYP11B2, CYP11B1 HPGD 586/4885LMNA 1197/4885EPHX2 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.